Severe Hidradenitis Suppurativa
An advanced, severe inflammatory skin condition causing deep, painful boils, interconnecting tunnels, and extensive scarring in the armpits and groin.
Emergency Management: Acute severe sepsis requiring IV antibiotics and emergent incision and drainage of a massive tense abscess to relieve pressure.
Severe Hidradenitis Suppurativa (HS), classified as Hurley Stage III, is a chronic, debilitating inflammatory skin disease characterized by widespread, diffuse involvement of apocrine gland-bearing areas (axillae, groin, perineum, inframammary regions) with multiple interconnected sinus tracts, extensive scarring, and chronic purulent discharge.
Detailed Overview
Unlike mild HS which presents with isolated nodules, Hurley Stage III involves coalescing lesions that form a dense network of fistulas and hypertrophic scars across entire anatomic regions. The pathogenesis begins with follicular hyperkeratosis and occlusion, followed by follicular rupture, intense immune activation (TNF-alpha, IL-17, IL-23), and deep tissue destruction. Secondary bacterial colonization often occurs but is not the primary cause. Stage III HS severely impacts the patient's quality of life, causing profound chronic pain, malodor, limited mobility, and psychosocial distress.
Epidemiology & Demographics
HS affects ~1-4% of the population, but only a minority progress to Hurley Stage III. It is more common in females (3:1) and typically begins post-puberty. Severe disease is more prevalent in patients of African descent.
Etiological Mechanism
A complex interplay of genetic predisposition, immune dysregulation, and environmental triggers (smoking, obesity) leading to follicular hyperkeratosis and plugging.
Primary Causes
["Autoinflammatory follicular occlusion", "Genetic mutations (e.g., NCSTN, PSENEN, PSEN1 genes affecting the gamma-secretase complex)", "Hormonal influences (androgens)"]
The primary event is infundibular hyperkeratosis of the terminal hair follicle leading to occlusion. Sebaceous and apocrine glands continue secreting, causing the follicle to dilate and eventually rupture, spilling keratin, hair, and bacteria into the dermis. This triggers a massive, chronic innate and adaptive immune response (involving macrophages, neutrophils, Th1, and Th17 cells). In Stage III, continuous cycles of inflammation and attempted healing lead to the epithelialization of deep dermal abscesses, forming complex, permanent interconnecting sinus tracts and widespread fibrotic scarring.
Diagnostic Criteria & Guidelines
Clinical diagnosis based on three criteria: 1) Typical lesions (deep-seated nodules, sinus tracts, comedones), 2) Typical topography (axillae, groin, perineum, submammary), and 3) Chronicity and recurrence (active disease for months/years). Hurley Stage III is defined by diffuse involvement with interconnecting sinus tracts and abscesses.
Biologic therapy is the cornerstone for Stage III to cool down inflammation prior to surgery. Adalimumab 160 mg SQ on Day 1, 80 mg SQ on Day 15, then 40 mg SQ weekly. Often combined with oral antibiotics like Clindamycin 300 mg BID and Rifampin 300 mg BID for 10-12 weeks.
Second-Line & Adjunctive Therapy
Secukinumab 300 mg SQ weekly for 5 weeks, then every 4 weeks. Infliximab (IV, off-label) 5 mg/kg at 0, 2, 6 weeks then every 8 weeks for rapid, refractory disease control.
Surgical & Procedural Management
Medical therapy alone is rarely curative for Stage III. Wide local excision (en bloc excision) of the entire apocrine-bearing area with all sinus tracts, followed by healing by secondary intention, skin grafting, or flap reconstruction is definitive.
Patient Counseling & Advice
Set realistic expectations: medical therapy reduces flares and drainage but cannot remove permanent scars or sinus tracts; surgery is eventually needed. Address the profound psychological impact (depression screening).
Follow-Up & Monitoring Schedule
Monthly visits during initiation of biologics to monitor response and side effects; coordinate closely with plastic/general surgery for surgical planning.
Preventive Strategies
Early aggressive treatment of Hurley I/II stages to prevent progression to Stage III scarring.
Without wide surgical excision, Stage III HS is lifelong, relapsing, and progressively scarring. With extensive en bloc resection, local recurrence rates are low (<10%), though new areas may develop.